Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1379476-75-1 | MDL No. : | MFCD23701644 |
Formula : | C15H24BN3O4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | GHPCJQQHZGRNDJ-UHFFFAOYSA-N |
M.W : | 321.18 | Pubchem ID : | 71463922 |
Synonyms : |
|
Num. heavy atoms : | 23 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.6 |
Num. rotatable bonds : | 5 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 96.23 |
TPSA : | 86.13 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.38 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.24 |
Log Po/w (WLOGP) : | -0.63 |
Log Po/w (MLOGP) : | 0.16 |
Log Po/w (SILICOS-IT) : | -0.93 |
Consensus Log Po/w : | -0.03 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.48 |
Solubility : | 1.07 mg/ml ; 0.00335 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.65 |
Solubility : | 0.725 mg/ml ; 0.00226 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.96 |
Solubility : | 3.5 mg/ml ; 0.0109 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.05 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338-P310 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
36% | With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 In 1,4-dioxane; water at 80 - 85℃; for 16.5h; Inert atmosphere; | 60 Example 60: tert-Butyl 4-(5-(l-isopropyl-7-methyl-6-(((6-methyl-2-oxo-4-propyl-l,2-dihydro pyridin-3-yl)methyl)carbamoyl)-lH-indol-4-yl)-3-methylpyridin-2-yl) piperazine-1- carboxylate To a solution of 4-bromo-l-isopropyl-7-methyl-N-((6-methyl-2-oxo-4- propyl- 1,2-dihydro pyridin-3-yl)methyl)-lH-indole-6-carboxamide (Example 30, 300 mg, 0.654 mmol) and (6-(4-(tert-butoxy carbonyl)piperazin-l-yl)-5-methylpyridin-3- yl)boronic acid (294 mg, 0.916 mmol) in 1,4-dioxane (5 mL) was added water (2.500 mL) and bubbled argon gas for 30 minutes. PdCi2(dppf)-CH2Ci2 adduct (53.4 mg, 0.065 mmol) was added and the reaction mass was stirred at 80-85 °C for 16 h. After completion of reaction, the reaction mixture was cooled to RT, filtered through celite, added water, extracted with ethyl acetate, concentrated and purified by column chromatography (silica gel, 5 % MeOH in chloroform) to obtain the title compound. Yield (36 ); JH NMR (CDC13, 300 MHz): δ 11.47 (s, 1H), 8.30 (s, 1H), 8.02 (s, 1H), 7.72 (s, 1H), 7.61 (s, 1H), 6.90 (s, 1H), 6.53 (s, 1H), 5.88 (s, 1H), 5.22 (s, 1H), 4.30 (s, 2H), 3.48 (bs, 4H), 3.06 (bs, 4H), 2.66 (s, 3H), 2.49 (m, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 1.53 (m, 2H), 1.46 (d, 6H, J=6.6Hz), 1.42 (s, 9H), 0.95 (m, 3H); MS (ESI+): m/z 654 (M- 1)+; HPLC purity 97.48 % |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate In water; N,N-dimethyl-formamide at 100℃; |
[ 883231-20-7 ]
(6-((tert-Butoxycarbonyl)amino)pyridin-3-yl)boronic acid
Similarity: 0.79
[ 936353-84-3 ]
(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)boronic acid
Similarity: 0.67
[ 1150114-75-2 ]
(6-(Pyrrolidin-1-yl)pyridin-3-yl)boronic acid
Similarity: 0.63
[ 2102451-30-7 ]
(1-(tert-Butoxycarbonyl)-1H-indol-4-yl)boronic acid
Similarity: 0.63
[ 940284-98-0 ]
tert-Butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylate
Similarity: 0.61
[ 883231-20-7 ]
(6-((tert-Butoxycarbonyl)amino)pyridin-3-yl)boronic acid
Similarity: 0.79
[ 2102451-30-7 ]
(1-(tert-Butoxycarbonyl)-1H-indol-4-yl)boronic acid
Similarity: 0.63
[ 1198408-35-3 ]
tert-Butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate
Similarity: 0.62
[ 940284-98-0 ]
tert-Butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylate
Similarity: 0.61
[ 571189-16-7 ]
tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
Similarity: 0.60
[ 883231-20-7 ]
(6-((tert-Butoxycarbonyl)amino)pyridin-3-yl)boronic acid
Similarity: 0.79
[ 936353-84-3 ]
(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)boronic acid
Similarity: 0.67
[ 1150114-75-2 ]
(6-(Pyrrolidin-1-yl)pyridin-3-yl)boronic acid
Similarity: 0.63
[ 1198408-35-3 ]
tert-Butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate
Similarity: 0.62
[ 571189-16-7 ]
tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
Similarity: 0.60
[ 936353-84-3 ]
(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)boronic acid
Similarity: 0.67
[ 940284-98-0 ]
tert-Butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)piperazine-1-carboxylate
Similarity: 0.61
[ 571189-16-7 ]
tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
Similarity: 0.60
[ 1150114-76-3 ]
(4-(4-(tert-Butoxycarbonyl)piperazine-1-carbonyl)phenyl)boronic acid
Similarity: 0.59
[ 470478-90-1 ]
tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate
Similarity: 0.57